# MEK162 for Patients With RAS/RAF/MEK Activated Tumors

> **NCT01885195** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 110 (actual)

## Conditions studied

- Solid Tumor and Hematologic Malignancies

## Interventions

- **DRUG:** MEK162

## Key facts

- **NCT ID:** NCT01885195
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-10
- **Primary completion:** 2015-10-01
- **Final completion:** 2017-04-11
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01885195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01885195, "MEK162 for Patients With RAS/RAF/MEK Activated Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01885195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*